Ciprofloxacin in Dextrose (5%) Injection, USP, 400 mg in 200 mL 5% Dextrose, Rx only, Manufactured for: Claris Lifesciences Inc. North Brunswick NJ, 08902, By: Claris Injectable Ltd. Gujarat, India, NDC 36000-009-24
Published April 5, 2017 · Recall initiated: March 10, 2017
Summary
FDA records drug Class II recall D-0613-2017, published April 5, 2017 and initiated March 10, 2017. Recalling firm: Claris Lifesciences Inc; Status: Terminated; Reported quantity: 18,360 units (765 cartons x 24 bags); Lot: Lot #: A051288, Exp. Sep 2017. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Claris Lifesciences Inc
- Distributor
- Nationwide
- Lot
- Lot #: A051288, Exp. Sep 2017
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDACiprofloxacin in Dextrose (5%) Injection, USP 200 mg in 100 mL 5% Dextrose, Rx Only, (2 mg/mL), 100 mLDecember 27, 2017
- FDAFluconazole Injection, USP, 400 mg in 200 mL, Rx only, Manufactured for: Claris Lifesciences Inc. NorthApril 5, 2017
- FDALevofloxacin Injection in 5% Dextrose, 750 mg in 150 mL 5% Dextrose, Rx only, Manufactured for: ClarisApril 5, 2017
- FDAMetronidazole Injection, USP, 500 mg/100 mL, Rx only, Manufactured for: Claris Lifesciences Inc. NorthApril 5, 2017
- FDAEndurant / Endurant II 23mm and 25mm Bifurcated Stent Graft Systems Model Numbers: ETBF2516C145E ETBF2516C166EMarch 29, 2017
- FDAHitachi Echelon MRI SystemMarch 29, 2017
Questions about this recall
Was Ciprofloxacin in Dextrose (5%) Injection, USP, 400 mg in 200 mL 5% Dextrose, Rx only, Manufactured for: Claris Lifesciences Inc. North Brunswick NJ, 08902, By: Claris Injectable Ltd. Gujarat, India, NDC 36000-009-24 recalled?
Yes. FDA published recall D-0613-2017 on April 5, 2017. Reported hazard: Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.
What should I do if I have this product?
Voluntary: Firm initiated · Letter